January 15, 2016

(ED NOTE: We receive no advertsing fees from this service, but just ran across it on the net, and thought would publish it.  Now, more extensive tumor analysis is available, with increasingly sophisticated modes of analysis)

Caris Molecular Intelligence

Evidence-Based Tumor Profiling Service

Utilizing multiple evidence-guided technologies — including IHC, FISH/CISH, PCR and Next-Generation Sequencing (NGS) — Caris Molecular Intelligence® provides oncologists with the most relevant, clinically actionable and individualized treatment information to personalize cancer care for all solid tumors. Our suite of tumor profiling services allows the physician to customize the level of profiling they deem necessary for each patient.

Caris Molecular Intelligence can be used to inform treatment selection within the standard of care, as well as to reveal treatment alternatives when the standard of care has been exhausted, when there are co-morbidities, or in cases of highly aggressive or rare tumors, metastatic disease or unresectable tumors.

Caris Molecular Intelligence:

  • Uses a combination of technologies, including NGS, to interrogate each tumor at the various biological stages of cancer
  • Is based upon an extensive review of the world’s clinical literature correlating biomarkers to drug response
  • Associates therapeutic agents with benefit or lack of benefit
  • May reveal treatments not previously considered
  • Identifies open, relevant clinical trials based on the patient’s expressed biomarkers with our Clinical Trials Connector

Caris’ tumor profiling services are available in several levels of service using multiple cancer profiling technologies.

Caris Life Sciences® Tumor Profiling Service offers complete tumor analysis coupled with an extensive clinical literature review. By matching potential therapies to patient-specific biomarker information, Caris Molecular Intelligence® provides the clinically relevant, patient-specific information doctors need to individualize cancer treatment.

Sophisticated Tumor Interrogation and Analysis

  • DNA sequencing, polymerase chain reaction (PCR) and next-generation sequencing* — identify mutations
  • Fluorescence (FISH) and chromogenic (CISH) in situ hybridization – detect gene rearrangements and gene copy number variations
  • Immunohistochemistry (IHC) – determines a biomarker’s level of protein expression
  • Fluorescence (FISH) and chromogenic (CISH) in situ hybridization – detect gene rearrangements and gene copy number variations
  • Immunohistochemistry (IHC) – determines a biomarker’s level of protein expression
  • Extensive Clinical Literature Assessment

    • Maintains an up-to-date repository of the world’s most relevant clinical literature
    • Caris has reviewed over 120,000 clinical literature manuscripts
    • Reviews and evaluates studies based on the strength of clinical evidence supporting associations between biomarkers and treatments
    • Performed by disease-specific clinical advisory boards and a team of Ph.D. scientists, oncologists and pathologists
  • Molecular Profiling to Identify Biomarkers

    Strength in numbers

    Some studies estimate that after initial treatment fails, as many as 95% of cancer patients will not respond to the next treatment suggested by conventional methods. However, burgeoning research in biomarkers and their relevance to cancer therapies is changing how we approach the characterization and treatment of cancers.

    Strength in information

    Biomarkers provide unique clues about each patient’s cancer—which treatments are more likely to be effective, and just as importantly, which therapies are more likely to fail. Armed with focused genetic and molecular information about their patient’s distinct disease, physicians can develop personalized treatment strategies designed for maximum effectiveness.

    Strength in results

    In a pilot study*, nine different centers used molecular profiling of patients’ tumors to identify potential biomarkers and help guide treatment for refractory cancer. Molecular targets were detected in nearly all of the patients, and of those where targets were found, 27% found success in secondary treatment options, allowing them to experience a longer, progression-free survival.


No comments

Be the first one to leave a comment.

Post a Comment